| dc.contributor.author | Al-Juffali, Noura | |
| dc.date.accessioned | 2023-02-01T19:40:05Z | |
| dc.date.available | 2023-02-01T19:40:05Z | |
| dc.date.issued | 2022-08 | |
| dc.identifier.citation | Oyesanya, M., & Al-Juffali, N. (2022). Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders? BJPsych Advances, 28(5), 281-285. | en |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1168 | |
| dc.description | Available with an NHS OpenAthens log in for eligible users | en |
| dc.description.abstract | Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety and effectiveness of the wakefulness-promoting agent, modafinil, as an adjunct to standard care in the mitigation of negative and cognitive symptoms of schizophrenia. Add-on modafinil, compared to add-on placebo and standard treatment, did not result in a clear benefit. Due to the heterogenous body of evidence, the quality of which ranged from very low to moderate, the review's conclusions are equivocal. | en |
| dc.description.uri | https://doi.org/10.1192/bja.2022.36 | en |
| dc.language.iso | en | en |
| dc.subject | Psychosis | en |
| dc.subject | Schizophrenia | en |
| dc.subject | Antipsychotics | en |
| dc.title | Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders? | en |
| dc.type | Article | en |